NASDAQ:OGI - OrganiGram Stock Price, Forecast & News

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OGI stock has increased by 4.7% and is now trading at $1.80. View which stocks have been mosted impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for OrganiGram.

OrganiGram is scheduled to release its next quarterly earnings announcement on Monday, April 20th 2020. View our earnings forecast for OrganiGram.

OrganiGram Holdings Inc (NASDAQ:OGI) posted its earnings results on Tuesday, January, 14th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. The company had revenue of $19.02 million for the quarter, compared to the consensus estimate of $14.74 million. OrganiGram had a negative net margin of 42.78% and a negative return on equity of 6.13%. View OrganiGram's earnings history.

11 analysts have issued 12-month price targets for OrganiGram's shares. Their forecasts range from $1.72 to $12.00. On average, they expect OrganiGram's share price to reach $7.54 in the next year. This suggests a possible upside of 318.7% from the stock's current price. View analysts' price targets for OrganiGram.

News coverage about OGI stock has trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. OrganiGram earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOrganiGram.

Some companies that are related to OrganiGram include Pacira Biosciences (PCRX), Dicerna Pharmaceuticals (DRNA), Karyopharm Therapeutics (KPTI), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), ZEALAND PHARMA/S (ZEAL), CytoDyn (CYDY), Innoviva (INVA), Ligand Pharmaceuticals (LGND), Zogenix (ZGNX), I-Mab (ARQT), Tricida (TCDA), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Enanta Pharmaceuticals (ENTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Aphria (APHA), KushCo (KSHB), Charlotte's Web (CWBHF), Innovative Industrial Properties (IIPR), NVIDIA (NVDA), Tilray (TLRY) and Alibaba Group (BABA).

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OGI stock can currently be purchased for approximately $1.80.

OrganiGram has a market capitalization of $311.54 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe. View additional information about OrganiGram.

The official website for OrganiGram is http://www.organigram.ca/.

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.